Monitoring age-related macular degeneration using artificial intelligence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to predict the progression of early and intermediate age-related macular degeneration (AMD) to advanced AMD over a two-year period. It will utilize advanced imaging techniques to identify changes in the retina and assess individual risk factors for disease progression. Patients aged 55-99 with early or intermediate AMD will be monitored at six-month intervals to evaluate clinical changes. The study seeks to enhance AMD classification through the integration of artificial intelligence with traditional assessment methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: 55-99 years old
* Early or intermediate AMD in at least one eye (drusen \> 63 µm and/or any definite hyper- or hypopigmentary abnormalities with or without reticular pseudodrusen)
* If both eyes are eligible, both eyes will be included in the cohort study.
* Clear optical media and adequate pupillary dilation for imaging and functional testing.

Exclusion Criteria:

* Any surgical treatment of the eye within 3 months prior to baseline in the study eye
* History of anti-VEGF treatment in the study eye before baseline
* History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye
* History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio \> 0.9
* Any concurrent intraocular condition in the study eye (e.g. advanced cataract or moderate/severe diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition
* Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery and YAG capsulotomy) during the study period
* Presence of corneal decompensation, haze or scarring with an impact on BCVA
* Refractive error larger than 6 diopters. In case of pseudophakia or refractive surgery: History of refractive error larger than 6 diopters.
* Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine or tamoxifen)
* Presence of active macular neovascularization at baseline

Where it's running

• CHU Dijon
  Dijon, France Recruiting
• University Medical Center Ljubljana
  Ljubljana, Slovenia Recruiting
• Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomed
  Barcelona, Spain Recruiting
• Vista Klinik Binningen
  Binningen, Switzerland Recruiting
• University of Zürich
  Zurich, Switzerland Recruiting
• Queen's Unviversity Belfast
  Belfast, United Kingdom Recruiting

Study contacts

• Study coordinator: Gregor Reiter, Priv.-Doz. Ing. DDr., BA MSc
• Email: gregor.reiter@meduniwien.ac.at
• Phone: +43 1 40400-73419

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• First-in-human test of ARO-033 in adults

  This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.

  Recruiting Phase 1 Arrowhead Pharmaceuticals · Auckland · NCT07662096

• Predicting Risk of AMD Progression Using Imaging in Aging Eyes

  Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.

  Recruiting at 2 sites Singapore National Eye Centre · Singapore and 1 other locations · NCT07653269

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Central microperimetry and radial OCT in geographic atrophy

  We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07556406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.